Available Technology


ViralFx is an integrated approach to the diagnosis and treatment of SARS-CoV-2 that is accurate, rapid, repeatable, and easily deployed

In pandemic scenarios, the capacity to complete laboratory diagnostic tests can be overwhelmed due to the need for specialized equipment and highly trained personnel to perform the complex workflows for detection of viral RNA. To address this challenge, an integrated antiviral diagnostic solution developed by Sandia can improve our nation’s ability to identify and rapidly respond to pandemic outbreaks and future emerging pathogens.

ViralFx integrates several Sandia technologies into a powerful and comprehensive solution ready for commercialization. QUASR (Quenching of Unincorporated Amplification Signal Reporters) is a technique to significantly enhance the favorable characteristics of LAMP (Loop-mediated Isothermal Amplification). SmartLAMP is a smartphone-based deployable diagnostic device to quickly assess potentially dangerous public health situations. When combined with Sandia’s portable SpinDx platform, which offers rapid detection of viral and host antigens without the need for sample preparation, ViralFx can enable the positive identification of SARS-CoV-2, rules out influenza or other coronaviruses, and diagnoses COVID-19 at all stages of the disease.

ViralFx may improve healthcare outcomes, minimize the strain on medical providers, maximize provider capacity to treat patients, improve dataset fidelity related to virus spread, and ultimately reduce the potential of spreading the virus, thus saving countless lives.


Detection of viral and host antigens

Determination of disease treatment’s effectiveness

Prevention of future outbreaks

Internal Laboratory Ref #: 
SD# 12060
Patent Issue Date: 
April 29, 2021
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin